KaydedilenlerDerginizi ekleyin

Dergiler / Haseki Tıp Bülteni / 2021 / Cilt: 59 - Sayı: 3

Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study

Şenay AĞIRGÖL
Muharrem AĞIRGÖL
Sayfa
239–244
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thirty-one patients had renalfailure, and 17 of them underwent renal transplantation, and the pruritus rate was high (57%) in the chronic renal disease Group.Conclusion: Pruritus is the most common side effect observed with DAA drugs used in treating hepatitis C and elderly patients, andpatients with comorbidity and renal transplantation are at high risk.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: As skin disorders may be observed with Hepatitis C, direct-acting antiviral drugs (DAA), dermatological side effects are alsoreported.
📊
Temel Bulgular & Veri:The objective is to determine the dermatological side effects of DAA drugs.Methods: A study was conducted with chronic hepatitis C patients who used Ombistavir/Paritaprevir/Ritonavir + Dasabuvir (Group1), Sofosbuvir + Ledispavir (Group 2), and sofosbuvir (Group 3) and who supplied the drugs from our hospital.
💡
Sonuç & Katkı:Thirty-one patients had renalfailure, and 17 of them underwent renal transplantation, and the pruritus rate was high (57%) in the chronic renal disease Group.Conclusion: Pruritus is the most common side effect observed with DAA drugs used in treating hepatitis C and elderly patients, andpatients with comorbidity and renal transplantation are at high risk.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aim: As skin disorders may be observed with Hepatitis C, direct-acting antiviral drugs (DAA), dermatological side effects are alsoreported. The objective is to determine the dermatological side effects of DAA drugs.Methods: A study was conducted with chronic hepatitis C patients who used Ombistavir/Paritaprevir/Ritonavir + Dasabuvir (Group1), Sofosbuvir + Ledispavir (Group 2), and sofosbuvir (Group 3) and who supplied the drugs from our hospital. Skin examinations ofthe patients regarding dermatological side effects were conducted. Patients with dermatological side effects and treatment modalitieswere followed.Results: One hundred twelve patients were using Group 1; 69 were using Group 2, 19 were using Group 3. All pruritus patients werein Group 1. It was detected in 56 of 200 patients (28%). Pruritus was more prevalent in patients with diabetes mellitus, hypertension,and heart disease, and the drug could be tolerated in those with no additional systemic comorbidities. Thirty-one patients had renalfailure, and 17 of them underwent renal transplantation, and the pruritus rate was high (57%) in the chronic renal disease Group.Conclusion: Pruritus is the most common side effect observed with DAA drugs used in treating hepatitis C and elderly patients, andpatients with comorbidity and renal transplantation are at high risk.

🔖

Bu Makaleye Atıf Yap

AĞIRGÖL, Ş., AĞIRGÖL, M. (2021). Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. Haseki Tıp Bülteni, Cilt: 59 - Sayı: 3, 239–244. https://ajindex.com/articles/347921

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128
  2. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801
  3. Arends JE, Kracht PA, Hoepelman AI; European Study Group for Viral Hepatitis (ESGVH). Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clin Microbiol Infect 2016;22:846-52
  4. Suntur BM, Kaya H, Eker HBŞ, Kara B, Bozok T, Unal N. A cross-sectional study of real life data of HCV from Turkey south region. J Infect Dev Ctries 2020;14:380-6
  5. Kirdar S, Aydin N, Tiryaki Y, Ertugrul B, Coskun A, Bilgen M. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018;126:109-13
  6. Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020;31:128-35
  7. Goetsch MR, Tamhane A, Varshney M, et al. Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/ Creatinine Ratios. Pathog Immun 2017;2:366-75
  8. Mikolas LA, Jacques K, Huq M, Krasner C, Mambourg SE. Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy. J Pharm Pract 2019;32:655-63
  9. Bourlière M, Pietri O. Hepatitis C virus therapy: No one will be left behind. Int J Antimicrob Agents 2019;53:755-60
  10. Piecha F, Gänßler JM, Ozga AK, et al. Treatment and retreatment results of HCV patients in the DAA era. PLoS One. 2020;15:0232773
  11. Chung CM, Nunley JR. Overview of hepatitis C and skin. Dermatol Nurs 2006;18:425-30
  12. Cacoub P, Bourlière M, Lübbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012;56:455- 63
  13. Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. Dig Dis Sci 2016;61:1692-9
  14. Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS. Overview of research on health-related quality of life in patients with chronic liver di